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Abstract 
Prenatal cell-free DNA (cfDNA) screening is now offered to pregnant women of all risk categories, 
creating a challenge in providing informed decision-making on a broad scale. Resources to support patient 
education, such as short educational videos, have been created to help ameliorate this issue but have not 
been formally evaluated. Thus, we sought to investigate the utility of videos in educating women about 
prenatal cfDNA screening and whether there were differences in knowledge and/or attitudes after viewing 
a video created by a non-profit genetics organization (Video A) versus a similar video created by a 
commercial testing company (Video B). Participants were asked to view one of the two videos and 
complete a survey assessing take-home messages, knowledge, attitudes, and demographics. 
A total of 207 individuals participated in the study; 106 viewed Video A (Group A) and 101 
viewed Video B (Group B). Mean knowledge scores for both groups indicated sufficient education by 
their respective videos; however, Group A scored significantly higher (mean = 9.40) than Group B (mean 
= 8.99) (p = <0.01). Both groups had favorable attitudes towards prenatal cfDNA screening with no 
significant difference between them. Other significant findings included younger participants having more 
positive attitudes than older participants (r(204) = -0.24, p = < .01), and those with a prior pregnancy 
having less favorable attitudes than those without ((17.1 versus 19.8) (204) = -3.09, p = <0.01). There 
were also notable qualitative differences in reported take-home messages between the groups: Group A 
more often addressed technical aspects of testing whereas Group B highlighted fetal sex determination 
and the timeline for testing. This study demonstrates that videos can effectively educate patients about 
prenatal cfDNA screening and that attitudes towards prenatal cfDNA screening are generally positive. 
However, the focus and origin of educational videos should be considered carefully by providers as these 






In the past several decades, prenatal screening options have grown from one available marker, maternal 
age, to many possible options for patients including nuchal translucency screening, maternal serum 
screening and, most recently, cell-free fetal DNA (cfDNA) screening, also known as non-invasive 
prenatal testing (NIPT) (ACOG Committee on Genetics, 2015; Rink & Norton, 2016; Russo et al., 2014; 
Wilson et al., 2013). As prenatal screening options continue to develop both in number and capability, 
patients are presented with an ever-increasing number of choices regarding the direction of their prenatal 
care. Currently, the American Congress of Obstetricians and Gynecologists (ACOG) recommends that all 
patients be offered the option of prenatal screening regardless of maternal age, meaning that an incredibly 
large number of women are faced daily with the decision of whether or not to undergo screening and what 
type to choose if they decide to do so (ACOG Committee on Practice Bulletins, 2016a, 2016b). Accurate 
explanation of various testing options and what each test can and cannot detect is vital in order for 
patients to make informed decisions, yet high patient volume, the brief time typically allotted for patient 
encounters, and other barriers often prevent appropriate pre-test counseling.  
It has long been a goal of the health care community to encourage patients to take a more active 
role in decisions regarding their care, particularly in obstetrics given the personal nature of prenatal 
testing. However, if patients are expected to make their own choices about the direction of their care it is 
essential that those decisions are informed by accurate information. This is important not only for ethical 
reasons, but also because informed decision-making has been shown to improve outcomes such as 
anxiety, decision conflict (uncertainty), and decision satisfaction (Marteau & Dormandy, 2001; Woolf et 
al., 2005). Nonetheless, a number of studies have demonstrated that many women feel they receive 
inadequate information about their prenatal screening options and that providers are not appropriately 
facilitating informed decision-making (Green et al., 2004; van den Berg et al., 2005; van den Berg et al., 
2006). In addition, providers themselves have reported difficulty explaining the complex nature of 
prenatal screening options to women, concern about making their patients more anxious, and difficulty 
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removing their own biases (Nagle et al., 2006; Nagle et al., 2008). Even those who do feel comfortable 
explaining prenatal screening options to their patients have cited multiple barriers to effective pre-test 
counseling including time, reimbursement, and lack of resources to assist in counseling (Farrell et al., 
2016). Ideally, all prenatal patients would see a genetic counselor to discuss their various options, as 
genetic counselors have the skills to present complex information in a simple and understandable way, 
with the time to discuss each option thoroughly with the patient. However, the small number of available 
genetic counseling providers makes this option currently unfeasible (Fonda Allen, Stoll, & Bernhardt, 
2016).  
One option to help providers facilitate informed decision-making is the use of decision aids such 
as videos, pamphlets, and computer modules as they “offer clinicians a validated format for presenting 
facts that surpass conventional advice in terms of balance, accuracy, and consistency” (Woolf et al., 
2005). Decision aids typically provide standardized information about treatment options and help patients 
to clarify their personal values as they may relate to possible outcomes, benefits, or risks. There have been 
several studies to date looking at the effectiveness of decision aids in facilitating informed 
decision-making in the context of prenatal screening and/or diagnostic testing, which have, in general, 
demonstrated an increase in knowledge and decreases in decision conflict, decision regret, and patient 
anxiety (Dugas et al., 2012; Graham et al., 2000; Hunter et al., 2005, Kupperman et al., 2009; Kupperman 
et al., 2014; Vlemmix et al., 2013; Yee et al., 2014). However, these previous studies did not address 
whether decision aids can help facilitate informed decision-making in regards to newer types of prenatal 
screening, particularly cfDNA screening.  
Genetics professionals and prenatal testing companies recognize the difficulty of facilitating 
informed decision-making now that technologies such as prenatal cfDNA screening are being offered to 
the general population and are beginning to create various resources to aid providers in patient education. 
One resource that has become widely utilized is that of short educational videos which prospective 
patients can view online or be shown in their physician’s office. A variety of companies and organizations 
have created videos to help explain the option of prenatal cfDNA screening to patients, yet the utility of 
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these resources in effectively educating individuals has not been formally tested. In addition, the fact that 
many of the available videos have been created by the testing companies themselves poses an important 
question: does the fact that the video could also be used as a marketing tool (as opposed to a video created 
by a group without a financial stake in test uptake) affect the viewer’s perceptions of the test and its 
benefits/limitations? A recent review of electronic resources and advertising for prenatal cfDNA 
screening found that while there were few instances of actual inaccuracy, there were multiple instances of 
the use of persuasive statements or arguments designed to appeal to the emotions of prospective mothers 
with concerns about risk. The study found that these statements often overstated the ability of the test to 
provide reassurance, aggressively promoted the safety of prenatal cfDNA screening, and were more likely 
to discuss test benefits than test limitations. In fact, only one third of the 40 resources analyzed were 
considered by the researchers to be “balanced” in the information they provided (Skirton et al., 2015). 
Thus, further investigation into the use of videos for patient education about prenatal cfDNA screening 
and the sources of those videos is warranted. 
Given that prenatal cfDNA screening is still fairly new, there have been several studies looking at 
attitudes towards this type of testing in both populations of pregnant women and in the general 
population. Several studies of pregnant women in the UK by Lewis, Hill, & Chitty (2016a, 2016b) found 
that the main motivation for uptake of prenatal cfDNA screening was reassurance and that women were 
extremely positive about the opportunity to have procedurally safe testing that reduced the need for 
invasive testing but was more accurate than previous screening options. In fact, the majority of the 
women interviewed felt that prenatal cfDNA screening should replace serum screening as first line 
testing. In 2015 and 2016, Allyse et al. looked at attitudes towards prenatal cfDNA screening in a large 
population of US adults of reproductive age and found moderate support for it with a high projected test 
uptake. The most highly rated aspects of the testing were its higher accuracy than other forms of serum 
screening, the fact that it could be performed early in pregnancy, and that it could provide potentially 
reassuring information.  
4 
We therefore sought to investigate the utility of videos in educating women about prenatal 
cfDNA screening and whether there were any differences in consequent knowledge and attitudes when 
using a video created by a non-profit genetics organization versus a similar video created by a commercial 
testing company. Attitudes about prenatal cfDNA screening were investigated to see if they supported the 
findings of previous studies. While the majority of previous studies about prenatal screening looking at 
similar parameters have involved the use of cohorts of pregnant women, we chose to recruit a non-clinical 
cohort of women of childbearing age from the general population as they represent the future patient 





Study design began with the selection of two videos about prenatal cfDNA screening, one created by a 
non-profit genetics organization (Video A) and one produced by a commercial testing company (Video 
B). The chosen videos were of a similar length and style, and covered similar content. We then 
customized a survey for the study, which was adapted from a validated instrument previously used to 
evaluate knowledge about NIPT amongst pregnant women (Lewis, Hill, & Chitty, 2015) and from the 
Maternal Serum Screening Knowledge Questionnaire (Goel et al., 1995). The original sources were 
adapted to reflect the fact that study participants were being drawn from a non-clinical cohort and did not 
have to be pregnant or have been pregnant previously in order to participate. The adapted survey included 
a ten question knowledge test about prenatal cfDNA screening, a five question attitude assessment, and 
questions regarding socioeconomic demographics and pregnancy history. We ensured that all ten 
questions on the knowledge test were answered by each video. In addition, an open-ended question 
inquiring about general take-home messages was included in an effort to probe more deeply into 
participants’ attitudes and impressions (the final survey is included in the Supplementary Material). At the 
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end of the survey, participants were given the option of providing their email address in order to be 
entered into a raffle for a $100 Amazon gift card.  
The adapted survey was piloted in a group of ten individuals, after which a few small changes to 
survey wording and formatting were made in response to feedback. In addition, a comment box was 
added at the end of the survey and the option “Not applicable - pregnancy ended in termination or 
miscarriage prior to testing” was added to Question 27 (see Supplementary Material).  
 
Recruitment and Randomization 
Individuals eligible for participation included English-speaking women in North America between ages 
20 and 45. There were no restrictions on current or prior pregnancy status. Recruitment took place on 
social media, email, and by word of mouth from January 26th, 2017 through February 10th, 2017 with the 
goal of recruiting at least 100 participants. After recruitment, participants were randomized into one of 
two groups: one group received Video A (Group A), and the other group received Video B (Group B). 
Each participant was sent an email with a link to their respective video and to the survey on 
SurveyMonkey. Both groups received identical surveys. Participants were asked not to watch their video 




After the survey closed, the knowledge test and attitude assessment scores for each participant were 
calculated. A score of 6 or greater (out of 10) on the knowledge test reflected adequate education, and a 
score of 13 or greater (out of 25) on the attitude assessment demonstrated a favorable attitude towards 
prenatal cfDNA screening. Mean knowledge and attitude scores for each study group and for various 
demographic subgroups were determined and compared for relevant differences using t-tests, one-way 
ANOVA, and post hoc analysis. Relevant differences between each group in terms of percent correct for 
individual questions on the knowledge test were determined using chi square and Fisher’s exact test.  
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Qualitative data from the open-ended question assessing main take-home messages was evaluated 
via open coding. The data was then was assessed for similarities and differences between the two groups.  
This study was determined to be exempt by the Sarah Lawrence College Internal Review Board.  
 
Results 
A total of 207 individuals participated in the study; 106 participants viewed Video A (Group A) and 101 
participants viewed Video B (Group B). Details of participant demographics can be found in Table 1. One 
participant was removed from the Group A dataset due to failure to complete the attitude assessment. In 
addition, six participants (two in Group A and four in Group B) did not provide their age and one 
individual in Group B did not provide her highest level of education completed. All seven participants 
were left in the dataset given that removal of these individuals did not significantly impact the results 
when analyses were rerun without their responses.  
 
Table 1: Participant Demographics  
 
  Total Group A Group B 
Number of Participants 206 105 101 
Age     
20-24 41 26 15 
25-29 85  39 46 
30-34 42  23 19 
35-39 25  12 13 
40-45 7  3 4 
Ethnicity     
White/Caucasian 156  81 75 
Black 8  1 7 
Hispanic 9  5 4 
7 
Asian 14 6  8 
Middle Eastern 5 2  3 
Mixed/Other 14  10 4 
Religion     
Yes 105 51  54 
Christian 72 36  36 
Jewish 14  7 7 
Muslim 8  4 4 
Hindu 2  1 1 
Other 9  3 6 
No 101  54 47 
Highest Education     
High School 0 0  0 
Partial College 18 11  7 
College 92  46 46 
Advanced Degree 95  48 47 
Profession     
Health Care Worker (incl. students) 92 46  46 
Genetic Counselor 34  17 17 
Doctor 5  3 2 
Nurse 12  4 8 
Other 41  22 19 
Not Health Care Worker 114 59  55 
Pregnancy History     
Previous Pregnancy 54 24 30 
Previous Screening 24  10 14 
No Previous Screening 16  7 9 
8 
Miscarriage or Termination 
Before Testing 
14  7 7 
No Previous Pregnancy 152  81 71 
  
Quantitative Data: 
The mean knowledge test scores for Group A and Group B indicated that both groups were sufficiently 
educated (with a score of 6 or more out of 10 correct) about prenatal cfDNA screening by their respective 
videos. However, participants in Group A scored significantly higher on the knowledge test (mean = 9.40) 
than those in Group B (mean = 8.99) (p = <0.01). Mean attitude assessment scores for both groups 
indicated favorable attitudes towards prenatal cfDNA screening (with a score of 13 or more out of 25). 
There was no significant difference in mean attitude scores between the two groups in relation to the 
video watched (Table 2). 
 















(SD = 0.92) 
8.99  
(SD = 1.06) 
0.41 2.97 <0.01 
Total Attitude Score 19.32 
(SD = 5.13) 
18.87  
(SD = 5.23) 
0.45  0 .63 n.s. 
*for two-tailed test 
  
Age  
For the total sample, age was negatively correlated with attitude (r(198) = -0.24, p = < 0.01), meaning that 
younger participants had more positive attitudes than older participants (Table 3). This was true for those 
in Group A (r(101) = -0.24, p = <0.05) and Group B (r(95)= -0.24, p = <0.05). Age was not related to 
knowledge in the total sample (r(198) = 0.05, n.s.). However, in Group B age appeared positively 
correlated with knowledge, although the result was not statistically significant (r(95) = 0.17, p = 0.10). 
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Table 3: Attitude Score Correlated with Age 














r = -0.24 <0.05 
          ​* for two-tailed test 
  
Education & Ethnicity 
A one-way ANOVA indicated that there was no significant difference in knowledge or attitude scores by 
education or ethnicity. This was true for the overall sample and each group individually. Post hoc 
comparisons in the total sample and the two subsamples resulted in similar findings. 
 
Health vs. Other Professions 
For the total sample, participants identifying as health care professionals had significantly higher 
knowledge scores (mean = 9.52 ) than participants identifying as non-health care professionals (mean = 
8.94) (t(202) = 4.42, p = <0.001) (Table 4). When examining the subsamples, it was found in Group A 
that being a health care professional was significantly related to knowledge, while this was not the case 
for Group B. For Group A, health care professionals had a mean knowledge score of 9.46 and 
non-healthcare professionals had a mean score of 8.60 (t(89) = 4.58, p = <0.001). For Group B, health 
care professionals had a mean knowledge score of 9.58 and non-health care professionals had a mean 





























(SD = 0.80) 
8.94  
(SD = 1.08) 




(SD = 4.70) 
18.72  
(SD = 5.23) 
0.85  1.18 n.s. 
*for two-tailed test 
 
The attitude scores of participants self-identifying as health care and non-health care 
professionals in the total sample were not significantly different (t(204) = 1.18, n.s.). This was true for 
both Group A (t (103) = 1.08, n.s.) and for Group B (t (99) = 0.61, n.s.).  
There were no significant differences in knowledge scores by type of health care profession in the 
total sample (F(5/79) = 0.75, n.s.), in Group A (F(5/36) = 0.70, n.s.) or in Group B (F(5/37) = 0.47, n.s.). 
However, attitude was related to type of health care professional in the total sample (F (5/79) = 3.78, p = 
<0.01). Post hoc analysis showed that the difference was between second year genetic counseling students 
(mean = 24.7) and other health care professions (mean = 20.0, p = <0.05), and between second year 
genetic counseling students (mean = 24.7) and those training in another health care profession (mean = 
19.8, p = <0.05). Attitude was also related to type of health care profession in Group A alone (F(5/36) = 
3.11, p = <0.05). Post hoc analysis showed that the difference was between second year genetic 
counseling students, who had a mean score of 24.3, and those training for another health care profession, 
who had a mean score of 15.8 on the attitude assessment (p = <0.05). There was no relationship between 
attitude and type of health care professional in Group B (F (5/37) = 1.36, n.s.). 
 
Previous Pregnancy 
There was no relationship between knowledge and whether or not the respondent had a previous 
pregnancy. However, attitude was related to having a prior pregnancy. In the total sample, those who had 
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a prior pregnancy had significantly less favorable attitudes towards prenatal cfDNA screening than those 
who did not have a prior pregnancy (17.1 versus 19.8) ((204) = -3.09, p = <0.01). The main source of this 
difference was in Group B where those who had a prior pregnancy had a mean score of 16.7 and those 
without a prior pregnancy had a mean of 19.8 (t (99) = -2.80, p = <0.01) (Table 5). 
 
Table 5 : Attitude Score and Prior Pregnancy Status 
  
 Mean for 
Prior Pregnancy 
Mean for 
No Prior Pregnancy 
Mean 
Difference 




(SD = 5.81) 
19.82 
(SD = 4.74) 




(SD = 6.39) 
19.84 
(SD = 4.61) 




(SD = 5.38) 
19.79 
(SD = 4.92) 
-3.09 -2.80 <0.01 
*for two-tailed test 
 
Religion 
There was no significant difference in knowledge or attitude scores for those who had a religious faith and 
those who did not. This was true in the total sample and in both subsamples. For the total sample and 
Group A, there were no significant differences in knowledge or attitude scores by religious preference. 
However, in a one-way ANOVA for Group B, knowledge was related to religious preference (F(3/50) = 
5.82, p = < 0.05). Post hoc tests revealed that the differences stemmed from Muslim participants with an 
average score of 7.00 versus Jewish participants with an average score of 9.57 (p = <0.01) and Christians 
with an average score of 8.94 (p = <0.01). Religion was not related to attitude score in Group B. There 
were no significant differences in knowledge or attitude scores by reported degree of religiosity in either 





Individual Knowledge Questions 
There were five statistically significant associations between which video was watched and answering a 
specific knowledge question correctly. Four of the five associations showed Video A as being correlated 
with higher knowledge. More participants who viewed Video A knew that prenatal cfDNA screening does 
not look for all possible genetic conditions; 94.3% of those who saw Video A knew the correct answer 
while only 72.3% of those who saw Video B knew the correct answer (Chi-square(1) = 18.10, p = 
<0.001). More participants who watched Video A knew that women with a test result showing decreased 
risk cannot be sure that their baby will not have Down Syndrome; while only 9 people overall answered 
incorrectly, 8 of the 9 (88.9%) were those who saw Video B (Fisher’s exact probability = <0.05). More 
participants who viewed Video A knew that prenatal cfDNA screening cannot be done as early as six 
weeks of the pregnancy (86.7% versus 74.3%); 40 participants responded incorrectly and 26 of the 40 
(65%) were those who viewed Video B (Chi-square(1) = 5.07, p = <0.05). More participants who viewed 
Video A knew that prenatal cfDNA screening cannot cause a miscarriage (Chi-square(1) = 5.00, p = 
<0.05); only 11 participants overall had the incorrect answer, but 9 of the 11 (81.8%) saw Video B. 
Only one question was associated with a higher knowledge score after watching Video B; 97.0% 
of those who viewed Video B correctly knew that prenatal cfDNA screening can determine the sex of the 
fetus, while only 79.2% of those who saw Video A were able to answer the same question correctly 
(Chi-square(1) = 15.40, p<0.001). Of the 25 participants who did not know that the test can determine the 
sex of the fetus, 22 of them (88.0%) were from Group A. 
 
Qualitative Data 
Our qualitative data was derived from the open-answer question inquiring about main take-home 
messages that was answered by all participants regarding their respective video. There were 206 
responses in total. We began by reading over the responses multiple times to identify common themes and 
counted 14 separate themes. Each answer was then broken down into these separate themes and tallied. 
While these themes were distinct, many of them were linked and fell into overarching categories. We 
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decided upon three separate categories to address different aspects of the videos including: breadth of 
testing, decisional considerations, and video. Every response included at least one theme and then was 
placed into the larger category. We also had an additional comments section as part of the survey. These 
responses were not included as part of the qualitative data as they were repetitive and often provided 
summaries, and therefore did not represent any additional data.  
 
Breadth of Testing 
There were a number of similar concepts amongst the answers that participants in both groups provided 
regarding the coverage of prenatal cfDNA screening as well as its limitations. One such common theme 
was the fact that prenatal cfDNA screening is non-invasive and poses no risk to the fetus. Statements 
coded in this theme included words such as ‘safe,’ ‘not harmful,’ and ‘little risk,’ indicating the perceived 
belief that both groups considered prenatal cfDNA screening to be safe overall. Another common theme 
that was shared by both groups was the fact that prenatal cfDNA screening can assess the risk of the fetus 
having a genetic condition. Phrases that represented this theme ranged from quantifying a ‘low or high’ 
risk of the fetus having abnormalities, as well as the ‘probability’ or ‘likelihood’ that the fetus would have 
a genetic condition. Similarly, both groups identified that the test can only look for certain genetic 
disorders or conditions. Participants noted that there were ‘several’ or ‘certain’ genetic disorders that were 
screened for, with some specifying further with terms such as ‘Down syndrome’ or ‘trisomies.’ 
The two groups differed quite noticeably concerning a number of different themes in this 
category. One included the screening being able to determine the gender or sex of the fetus. Only two 
participants in Group A noted this concept as a takeaway after watching their specific video; conversely, 
almost half of the participants from Group B included a statement referencing this fact. Another area in 
which the two groups differed was the length of gestation at which the screening could be offered. Close 
to half of Group B noted that prenatal cfDNA screening is an option as ‘early as nine weeks,’ ‘early on in 
the pregnancy,’ or ‘before other tests.’ Less than five participants in Group A included a similar statement 
in their answers, indicating a clear difference in the strength of this message between the two groups. 
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Another prevailing difference between the two groups was in their focus on the diagnostic value of the 
screening. Participants in Group A frequently noted that prenatal cfDNA screening is not diagnostic, 
including phrases such as ‘false positives,’ ‘not a guarantee,’ ‘imperfect,’ and ‘not definitive,’ in their 
answers. Very few participants in Group B made similar statements in their responses.  
 
Decisional Considerations 
There was less overlap between the groups concerning prenatal cfDNA screening and additional 
decisional considerations. The one area in which there was a similarity was the belief that prenatal cfDNA 
screening is easy. Participants in both Group A and Group B included this theme in their responses. Most 
phrases included ‘quick and easy’ and ‘simple,’ with one participant writing that prenatal cfDNA 
screening is easier as ‘compared to traditional methods.’ 
For the remaining themes in this category, no participants in Group B included such statements in 
their answers, while a sizeable number of Group A did. Participants in Group A were cognizant of a 
number of considerations factoring into decisions about undergoing prenatal cfDNA screening. One such 
theme included the idea that screening is ‘optional,’ a ‘personal choice,’ or ‘may not be worth it for some 
people.’ This belief was supported by a number of participants in Group A who also cited that prenatal 
cfDNA screening is just one of many screening options available. Answers ranged from ‘one of many 
options’ to ‘different types of testing.’ Additionally, participants in Group A noted that prenatal cfDNA 
screening is not without risks; common responses included ‘risks and benefits’ or ‘limitations’ for 
prenatal cfDNA screening. This belief was encapsulated by the following statement: “Mothers should 
think about what the results of this test mean for them.” Participants also cited that prenatal cfDNA 
screening is a combination of interesting, informative, or some iteration of ‘useful’ in their opinion, with 
one respondent stating that it is ‘an important part of the pregnancy process.’ A few participants spoke of 
prenatal cfDNA screening providing reassurance, including phrases such as ‘helpful for worried mothers.’ 
About the same number of participants in Group A also made reference to the fact that they considered 
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prenatal cfDNA screening to be more accurate as compared to other screening tests, for example, ‘better 
than other blood screening tests.’  
 
Video 
Overall, in both groups A and B there was little written by respondents regarding the video itself. One 
specific phrase that was included in a few answers given by participants in Group B was the idea of the 
video being an ‘advertisement.’  
 
Discussion 
The purpose of our study was to determine if two separate educational videos about prenatal cfDNA 
screening would be able to adequately educate a non-clinical cohort of female participants from the 
general population and to determine what attitudes participants held towards prenatal cfDNA screening. 
Analysis was then performed to determine if the above measures differed depending on whether the 
participant viewed Video A (produced by a non-profit genetics organization) versus Video B (produced 
by a commercial testing company). Overall, the results from this study showed that participants in both 
groups were sufficiently educated about prenatal cfDNA screening and held favorable attitudes towards 
prenatal cfDNA screening after viewing their respective videos. However, participants varied 
substantially in their main take-home messages depending on the video they watched. Our study is also 
notable in that participants were drawn from the general population, in contrast to participants in the 




Our study found that both videos were effective in providing participants with adequate information 
regarding prenatal cfDNA screening. This finding is consistent with those of previous studies which 
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showed that educational tools and decision aids can be effectively used as a means of educating patients 
about prenatal screening options (Dugas et al., 2012; Graham et al., 2000; Hewison et al., 2001; Hunter et 
al., 2005, Kupperman et al., 2009; Kupperman et al., 2014; Vlemmix et al., 2013; Yee et al., 2014). As 
prenatal cfDNA screening is a relatively new technology, no prior studies examined the utility of videos 
about prenatal cfDNA screening in effectively educating patients. In addition, no previous studies 
compared two different videos in their quality as educational tools. Our study showed that while both 
videos were effective in educating participants, participants in Group A had a significantly higher mean 
knowledge score as compared to those in Group B. This could speak to earlier research which showed 
that while there is not misinformation in videos produced by commercial testing companies, they often 
limit focus or place more emphasis on certain factors (Skirton et al., 2015). More research needs to be 
done comparing the effects of commercial videos versus non-commercial videos on patient education and 
attitudes. 
The results also showed that health care professionals had significantly higher knowledge scores 
when compared to non-health care professionals in both Group A and Group B, which were each roughly 
comprised of the same number of health care professionals. Previous similar studies did not include this 
demographic in their analyses. It stands to reason that prenatal cfDNA screening is a newer prenatal 
screening technology and therefore may not be as widely used or known by the general public. Health 
care professionals may have had more knowledge about prenatal cfDNA screening prior to watching the 
videos. They may also have been more familiar with similar screening methods and therefore were able to 
apply that knowledge when answering the survey questions.  
When the results from comparison of individual questions on the knowledge survey were 
analyzed, clear differences between the two groups in their answers to five specific questions were 
identified. Of the five questions, a significant number of respondents from Group A responded correctly 
to four of the questions, while those from Group B performed better on one question. The content of these 
specific questions suggests this finding could be explained by a difference in focus between the two 
videos. Group A performed significantly better on questions that addressed the scope of and technical 
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aspects of testing, such as the range of conditions screened for, while Group B performed significantly 
better when asked whether prenatal cfDNA screening could determine the biological sex of the fetus. One 
possible explanation for this finding is that prenatal cfDNA screening is advertised strategically to appeal 
to pregnant women, and such advertisements may be less focused on the technical aspects of testing and 
more focused on the positive aspects of testing such as early sex determination. In fact, prenatal cfDNA 
screening is commonly referred to as the ‘gender test’ by women seeking to pursue it. Thus, our findings 
indicate clear differences in the focus of information between the two videos. More research needs to be 
done to determine the informational focus of videos produced by commercial testing companies and to 
assess whether they provide balanced information to women seeking prenatal cfDNA screening.  
 
Attitudes 
Attitude assessment results showed that respondents from both groups viewed prenatal cfDNA screening 
favorably after watching their respective videos and that there was no significant difference in attitude 
scores between the two groups or between any of the demographic subgroups. This finding is similar to 
other studies concerning prenatal cfDNA screening, which found that most participants viewed this type 
of prenatal screening favorably (Allyse et al., 2014; Georgsson et al., 2016; Kelly & Farrimond, 2011; 
Lewis et al., 2014; Lewis et al., 2016; Sahlin et al., 2016). However, several trends in attitudes amongst 
respondents were noted. One trend was that lower age corresponded to a more favorable attitude towards 
prenatal cfDNA screening. While there are no conclusive explanations for this phenomenon, younger 
respondents may be more receptive to genetic screening as it has recently become a more prevalent 
practice in the general population. Younger respondents may also be more likely to view screening as a 
mode of reassurance. In addition, older respondents could be cognizant of the fact that they are more 
likely to receive positive results and thus may feel more apprehensive towards screening tests. Another 
correlation was that participants with previous pregnancies held a less favorable attitude towards prenatal 
cfDNA screening. This hesitancy could be due to the newness of the screening and the fact that 
participants may not have had this specific type of screening in their previous pregnancies. Participants 
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with a prior pregnancy may also feel that they were able to have successful pregnancies without prenatal 
cfDNA screening and therefore consider it unnecessary. More research needs to be done to examine the 
reasons underlying these two trends.  
 
Qualitative Data 
There was a clear difference in the main take-home messages reported by the two groups after watching 
their respective videos. Despite the fact that both of the videos contained the same information necessary 
to answer the knowledge portion of the survey, respondents appeared to place importance on different 
aspects of the videos. Those in Group A often addressed the informative portions of the video such as the 
breadth and depth of testing. In contrast, respondents in Group B tended to focus on specific catch 
phrases, such as ‘gender’ or how early in pregnancy the screening could be performed. These findings 
reflect the trends seen in terms of performance between the two groups on certain knowledge test 
questions, and thus speak to the focus of the videos themselves. The main take-home messages reported 
by the participants also suggest that Video B (created by a commercial genetic testing company) functions 
as more of an advertisement than Video A (created by a non-profit genetics organization). This is 
something that should be considered by providers considering offering either of these videos as a means 
of patient education. Providers themselves often rely on commercial testing companies for education 
regarding prenatal cfDNA screening, so consideration of the source and potential slant of a video 
employed with patients is important (Farrell et al., 2016). 
 
Study Limitations 
There were some inherent limitations to our study. One limitation is that the sampling methodology 
resulted in a demographically homogeneous study sample. Most of the participants were Caucasian and 
college-educated. It could be said that the recruitment methods were not sufficient for representation of 
the general population; however, it could also be argued that this is the most relevant population to study 
currently because, as noted by Allyse et al. in their 2015 publication, this group is currently the population 
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with the most access to prenatal cfDNA screening. While our study cohort may not be as representative of 
the general population as desired, it serves as a foundation for more research.  
Another limitation is that videos alone are unable to address all of the relevant components that 
comprise informed consent, particularly in ensuring that women are making choices that are consistent 
with their values. Multiples prior studies have mentioned the importance of using educational tools that 
also take into account patient values, therefore acting as a more comprehensive decision aid (Lewis et al., 
2016; Stefansdottir et al., 2010; van den berg et al., 2005; van den berg et al., 2006; Vanstone et al., 
2014). While it would be ideal for patients to speak to their provider or a genetic counselor before seeking 
screening in order to clarify which options align with their values, the purpose of this study and previous 
similar studies has been to educate a population that may not have access to a genetic counselor or are 
considered low-risk. For this purpose, a solution would be to include videos like the ones in this study as 
part of a comprehensive interactive tool that both educates and enables participants to interact 
meaningfully in the decision-making process. This is doubly important given that multiple studies have 
cited concerns that prenatal cfDNA screening will become a part of routine blood work because of its 
non-invasive nature, thereby diminishing attention to informed consent as a result. (Allyse et al., 2015; 
Allyse et al., 2016; Dondorp et al., 2015). Without informed consent regarding prenatal cfDNA screening, 
women may have no preparation for the results they could receive.  
One potential limitation that could explain the significant difference in knowledge scores between 
the two groups is the particular videos that were included in this study. While they were matched to 
ensure a similar length and baseline amount of knowledge, there were aspects of each video that could not 
be controlled. The distinct focus of each video could also account for the varied qualitative responses, as 
previously discussed. 
 
Areas for Future Study 
While this study has contributed to a better understanding of patients and their experiences being educated 
about prenatal cfDNA screening at the present time, more research needs to be done in this area. One area 
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for future research would be comparison of knowledge gained by patients during counseling sessions in 
clinic versus knowledge gained from videos alone. There has been a dearth of studies comparing clinical, 
provider-based experiences and educational tool-based knowledge, particularly for prenatal cfDNA 
screening; such studies could be very illuminating and potentially useful. In addition, as mentioned 
before, educational videos could be part of a comprehensive decision aid that assists patients in making 
informed choices by including a values alignment component; further research should be done to test the 
impact of such a tool once it is developed. Lastly, another area of potential study is determining the 
impact of videos created by commercial testing companies on patient education. Countless videos about 
prenatal cfDNA screening have been produced by commercial testing companies and are available online. 
For a number of people, these videos could be their first encounter with information about prenatal 
cfDNA screening and thus could form the basis for the rest of their experience.  
 
Conclusions 
Our study suggests that videos can in fact effectively educate patients about prenatal cfDNA screening 
and that patients’ attitudes about prenatal cfDNA screening are positive overall. However, the focus and 
origin of a video should be carefully considered by providers prior to use as those factors seem to variably 
influence main take-home messages. Given that an increasing number of providers will likely be pursuing 
the use of alternative counseling aids such as videos to help facilitate informed consent and 
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1. Open Question: What is your main takeaway after watching this video (1-2 sentences)? 
 





5 or more 
 
Section Two: Knowledge Test 
 
For each of the following questions, please answer with one of the following options: True/False/Not Sure 
  
3.  Prenatal cfDNA screening involves taking blood from a pregnant woman’s arm. 
  
4. Prenatal cfDNA screening can tell you the sex of your baby (boy vs. girl). 
  
5. Prenatal cfDNA screening gives a Yes or No answer regarding if the baby has a 
genetic condition. 
  
6. Prenatal cfDNA screening looks for all possible genetic conditions. 
  
7. If a woman receives an “increased risk” result on prenatal cfDNA screening, further tests are needed in order to be 
able to tell if anything is truly wrong.  
  
8. Women who have a “decreased risk” result on prenatal cfDNA screening can be sure that their baby will not have 
Down syndrome. 
  
9. Prenatal cfDNA screening can test for chromosomal abnormalities other than Down Syndrome. 
  
10. Prenatal cfDNA screening is optional. 
 
11. Prenatal cfDNA screening can be done as early as 6 weeks of pregnancy. 
  
12. Having a test like prenatal cfDNA screening performed can cause a miscarriage. 
 
 
Section Three: Attitude Assessment 
 
For each of the following five questions, please circle the number from 1 to 5 that best describes how you feel 
at about each statement provided. If you are not currently pregnant, please answer the way you ​think you 
would feel if you were currently pregnant​. 
 












1 2 3 4 5 Strongly Agree 
  




1 2 3 4 5 Strongly Agree 
  
16. For me, having prenatal cfDNA screening would be reassuring: 
  
Strongly Disagree 1 2 3 4 5 Strongly Agree 
  
17. For me, having prenatal cfDNA screening would be desirable: 
  
Strongly Disagree 1 2 3 4 5 Strongly Agree 
 
 
Section Four: Demographic Survey 
 




















21. Do you have a religious faith? Yes/No 
 










23. If Yes, how religious are you? 
Very 
Somewhat 
Not at All 
 




25. If yes, what best describes your profession or training? 
Genetic counselor 
Genetic counseling student 
Physician 
Medical school student 
Nurse 
Nursing student 
Other health profession 
Training for another health profession 
 








N/A - Pregnancy ended in termination or miscarriage before testing 
 
28. If yes, what best describes the circumstances in which you underwent screening for Down syndrome: 
My healthcare provider ​offered​ the option of screening and I elected to undergo it 
My healthcare provider ​recommended​ that I undergo screening 
I requested screening for Down syndrome during my pregnancy 
 
29. If no, what best describes the reason that you did not undergo screening for Down syndrome: 
My healthcare provider ​offered​ screening for Down syndrome but I chose not to have it. 
My healthcare provider told me about the screening but did not recommend it for me 
I was never told about prenatal screening for Down syndrome during my pregnancy  
 
30. If you were offered screening for Down Syndrome in a prior pregnancy, and you decided not to have it done, 
what was the reason (check all that apply)? 
I did not feel a screening test would be helpful for me because I knew I wanted to have a diagnostic test 
(amniocentesis or CVS)  
I would never terminate an affected pregnancy so did not feel the information would be helpful for me 
If positive, I would never have an invasive test to confirm and put my pregnancy at risk 
It would have caused a lot of anxiety if I found out I was high risk 
Screening wouldn’t have given me a definite result  
My partner or family did not want me to 
I preferred not to know  
 












33. What was the outcome? 
Diagnosis of Down Syndrome 
Diagnosis of another condition 
Normal result 
Miscarriage as the result of an invasive test 
Not Sure 
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